



# NEWS RELEASE

## **RECORDATI EXTENDS ITS AGREEMENT WITH BERLIN CHEMIE IN GERMANY TO ITS NEW ANTIHYPERTENSIVE PRODUCT**

*Milan, 27 September 2007* – Recordati announces the signature of an addendum which extends its licensing agreement with Berlin Chemie (Menarini group) in Germany to the marketing and sales of its new antihypertensive product, a fixed combination of lercanidipine (a calcium channel blocker) and enalapril (an ACE inhibitor) – two drugs widely used for the treatment of high blood pressure.

Berlin Chemie already markets lercanidipine successfully on the German market under the brand name Carmen<sup>®</sup> and will launch the new product in October using the brand Carmen ACE<sup>®</sup>. Berlin Chemie will thus work alongside Merckle Recordati and Meda who started selling the product in Germany in April.

*Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), dedicated to the research, development, manufacturing and marketing of pharmaceuticals, with headquarters in Milan, Italy, operations in the main European countries, and a total staff of over 2,200. A European field force of over 1,100 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas. Recordati's current and growing coverage of the European pharmaceutical market makes it a partner of choice for new product licenses from companies which do not have European marketing organizations. Recordati is committed to the research of new drug entities within the cardiovascular and urogenital therapeutic areas in which its research team has proven scientific competence and a track record of discovery and development of original drugs, the most recent of which, lercanidipine, a latest generation calcium channel blocker for the treatment of hypertension, is the company's leading product. Consolidated revenue for 2006 was € 576.2 million, operating income was € 120.3 million and net income was € 74.0 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

### Investor Relations

Marianne Tatschke

(39)0248787393

e-mail: [inver@recordati.it](mailto:inver@recordati.it)

### Media Relations

Claudio Rossetti (Echo Comunicazione d'Impresa)

(39)02 62694736

e-mail: [crossetti@echocom.it](mailto:crossetti@echocom.it)

*Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements.*

*All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.*